Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaspargase-based concurrent chemoradiotherapy in stage I/II extranodal NK/T cell lymphoma
ChiCTR-OIC-15007662Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2016
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: two-year progression free survival rate. Planned start Mar 2016; status: not yet recruiting.
02
Drugs
pegaspargase
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR-OIC-15007662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-15007662.